Ashley Cordova is recorded as Board Member at NovoCure Ltd (NVCR) since June 4, 2025 and Head of Investor Relations at NovoCure Ltd (NVCR). The newest filing on record that lists Ashley Cordova as Board Member at NovoCure Ltd (NVCR) is dated April 20, 2026. NovoCure Ltd reported in an 8-K filed December 1, 2025 that Ashley Cordova resigned as Chief Executive Officer, effective November 30, 2025. NovoCure Ltd reported in an 8-K filed December 1, 2025 that Ashley Cordova resigned as Director, effective November 24, 2025. NovoCure Ltd reported in an 8-K filed June 6, 2025 that Ashley Cordova was appointed director, effective June 4, 2025. Equibles holds 5 filed executive changes naming Ashley Cordova; each is listed under recent activity with its source filing. The proxy statement of NovoCure Ltd reports total compensation of $13,198,354 for Ashley Cordova in fiscal 2025, including a base salary of $901,837. Disclosed compensation is on record for 6 fiscal years. Ashley Cordova has spoken on 22 earnings calls across 1 company, most recently for NovoCure Ltd on October 30, 2025. NovoCure Ltd is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at NovoCure Ltd includes Asaf Danziger (CEO and Board Member), David Hung (CEO and Board Member), Frank Leonard (CEO and Board Member) and 7 others.
“On November 24, 2025, by mutual agreement, Ashley Cordova, Director and Chief Executive Officer of NovoCure Limited (the "Company") resigned as a member of the Board of Directors of NovoCure Limited (the "Company"), effective immediately, and her position as Chief Executive Officer of the Company, effective November 30, 2025.”
NovoCure Ltd Form 8-K, filed December 1, 2025
· Read the filing
“On November 24, 2025, by mutual agreement, Ashley Cordova, Director and Chief Executive Officer of NovoCure Limited (the "Company") resigned as a member of the Board of Directors of NovoCure Limited (the "Company"), effective immediately, and her position as Chief Executive Officer of the Company, effective November 30, 2025.”
NovoCure Ltd Form 8-K, filed December 1, 2025
· Read the filing
Ashley Cordova on recent calls
“Earlier this year, we had an exciting presence at the ASCO Annual Meeting where data from PANOVA-3 were presented during the Saturday evening plenary with concurrent publication in the Journal of Clinical Oncology.”
“We are squarely focused on execution, and I am proud of what the team has delivered so far this year. We have reached multiple milestones on our path to bring Tumor Treating Fields to more patients and have additional catalysts on the horizon.”
“It has been an exciting quarter for our team, and I am proud of the milestones we've hit already this year. Our mission has never felt more urgent as we expand our reach to more patients facing some of the most challenging solid tumors with significant unmet needs.”
“I am honored to step into the role of Chief Executive Officer at this pivotal moment in NovoCure's history. Our mission has never felt more urgent as we expand our reach to patients facing some of the most challenging tumors with significant unmet needs.”
“It is an exciting time to be at NovoCure, and I am both humbled and energized by the opportunity to lead this company into a bright future. Throughout 2024, we have taken steps to return our GBM business to growth through a focus on prescription conversion, patient persistence, and cross-functional alignment.”
